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OBJECTIVE—Pigment epithelium–derived factor (PEDF) is an
adipocyte-secreted factor involved in the development of insulin
resistance in obesity. Previous studies have identiﬁed PEDF as
a regulator of triacylglycerol metabolism in the liver that may act
through adipose triglyceride lipase (ATGL). We used ATGL
2/2
mice to determine the role of PEDF in regulating lipid and glu-
cose metabolism.
RESEARCH DESIGN AND METHODS—Recombinant PEDF
was administered to ATGL
2/2 and wild-type mice, and whole-
body energy metabolism was studied by indirect calorimetry.
Adipose tissue lipolysis and skeletal muscle fatty acid metabo-
lism was determined in isolated tissue preparations. Muscle lipids
were assessed by electrospray ionization–tandem mass spec-
trometry. Whole-body insulin sensitivity and skeletal muscle glu-
cose uptake were assessed.
RESULTS—PEDF impaired the capacity to adjust substrate
selection, resulting in a delayed diurnal decline in the respiratory
exchange ratio, and suppressed daily fatty acid oxidation. PEDF
enhanced adipocyte lipolysis and triacylglycerol lipase activity
in skeletal muscle. Muscle fatty acid uptake and storage were
unaffected, whereas fatty acid oxidation was impaired. These
changes in lipid metabolism were abrogated in ATGL
2/2 mice
and were not attributable to hypothalamic actions. ATGL
2/2 mice
were also refractory to PEDF-mediated insulin resistance, but
this was not related to changes in lipid species in skeletal muscle.
CONCLUSIONS—The results are the ﬁrst direct demonstration
that 1) PEDF inﬂuences systemic fatty acid metabolism by pro-
moting lipolysis in an ATGL-dependent manner and reducing fatty
acid oxidation and 2) ATGL is required for the negative effects of
PEDF on insulin action. Diabetes 60:1458–1466, 2011
A
dipose tissue biology is markedly affected by
obesity, and its endocrine role has been ex-
tensively investigated. Studies using proteomic
approaches estimate that ;90–260 individual
proteins are released by adipocytes (1–4). Several adipose-
secreted factors that are elevated in obesity are implicated
in the pathogenesis of metabolic dysfunction and insulin
resistance, including tumor necrosis factor-a (5), interleukin-6
(6), resistin (7), and retinol-binding protein 4 (8). These data
support a major role for adipose tissue in regulating whole-
body fatty acid metabolism and insulin action.
Pigment epithelium–derived factor (PEDF, SerpinF1) is
upregulated in individuals with the metabolic syndrome
(9,10) and patients with type 2 diabetes (11,12). Although
PEDF is best known for its antiangiogenic and neuro-
protective functions (13), recent work has implicated
PEDF in the development of obesity-related insulin re-
sistance (3,14). PEDF induced proinﬂammatory signaling,
increased adipocyte lipolysis, and promoted lipid accu-
mulation in muscle and liver that was associated with in-
sulin resistance (3).
PEDF is thought to exert its biologic actions by binding
to a cell surface receptor (15,16). A recently identiﬁed
cell surface receptor that possesses phospholipase activity
was reported in retinal pigment epithelial cells (17). Sur-
prisingly, this putative PEDF receptor was reported to
be adipose triglyceride lipase (ATGL), a highly conserved
triacylglycerol lipase that is critical for the maintenance
of lipid and glucose homeostasis (18–23). Others have
shown that recombinant PEDF is transported into cells
and colocalizes with ATGL at lipid droplets, and coimmu-
noprecipitation studies indicate that ATGL interacts with
PEDF (24). PEDF-deﬁcient mice have hepatic steatosis,
and some evidence supports the premise that the PEDF–
ATGL nexus may be important in conveying PEDF’sm o d -
ulation of lipid metabolism (24).
In the current study, we used pharmacologic and genetic
models to examine the role of PEDF in systemic fatty acid
metabolism. We tested the hypothesis that ATGL is re-
quired for the metabolic actions of PEDF.
RESEARCH DESIGN AND METHODS
Cell culture. L6 myoblasts and 3T3-L1 adipocytes were maintained as de-
scribed in the Supplementary Methods. Recombinant PEDF was puriﬁed from
a HEK293 cell line stably transfected with human PEDF (25).
Animal maintenance and experimental protocols. Experimental proce-
dures were approved by the School of Biomedical Sciences Animal Ethics
Committee (Monash University) and conformed to National Health & Medical
Research Council (Australia) guidelines regarding the care and use of exper-
imental animals. ATGL and hormone-sensitive lipase (HSL)
2/2 mice were
generated as described (18,26). Knockout and wild-type (Wt) mice were gen-
erated by breeding heterozygous mice for the deleted allele. Mice were housed
under controlled temperature (;22°C) and a 12-h light/dark cycle and had free
access to standard mouse chow and water. Female or male mice were aged
9–12 weeks.
For the refeeding studies, mice were fasted for 16 h and killed, or fasted for
24 h then provided access to food for 2 h before being killed. For in vivo PEDF
administration experiments, mice were allowed ad libitum access to food or
were fasted for 8 h, injected with 0.9% saline or PEDF, then maintained until
being killed 8 h later. For ex vivo metabolic analysis, mice were fasted for 4 h
and assays were performed at 1100. For the intracerebroventricular (ICV)
experiments, male C57BL/6 mice were anesthetized under isoﬂurane and placed
in a stereotaxic device. A guide cannula (Plastics One, Roanoke, VA) was im-
plantedinto theleftlateral ventricle(anteroposterior 20.3 mm, lateral +1.0 mm to
bregma and dorsoventral 22.5 mm below skull). The support plate of thecannula
was attached to the skull, and the mice were allowed 4 days of recovery.
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ORIGINAL ARTICLEMetabolic assessment. Whole-body metabolic monitoring was performed in
a Comprehensive Laboratory Animal Monitoring System (Columbus Instru-
ments, Columbus, OH). Mice were housed individually in closed chambers
for 60 h for assessment of oxygen uptake, carbon dioxide production, activity,
and food intake. Mice were injected with PEDF (50 mg i.p.), or for ICV
experiments, mice were injected with a 2.5-mL volume of artiﬁcial cerebro-
spinal ﬂuid (aCSF) or PEDF (0.365 mg/mL) before the onset of the dark phase.
All compounds were injected using a 28-gauge stainless steel injector placed
in and projecting 0.5 mm below the tip of the cannula.
Lipolysis. 3T3-L1 adipocytes or isolated epididymal fat were incubated in
Krebs buffer, 2% BSA, and glucose (8 mmol/L) for 2 h. PEDF (100 nmol/L) or
isoproterenol (1 mmol/L) were added as indicated. Glycerol (Sigma, St. Louis,
MO) and free fatty acid (FFA; Wako, Richmond, VA) were analyzed using
commercial assays.
Fatty acid metabolism. Fatty acid metabolism was assessed in myotubes or
isolated muscles as described previously (27).
Mitochondrial isolation and respiration. Mitochondrial isolation and res-
piration were performed as described in the Supplementary Methods.
Triacylglycerol hydrolase activity. Cell lysates were incubated in asubstrate
consisting of 5 mmol/L triolein, 14 3 10
6 dpm [9, 10-
3H] triolein, 0.6 mg phos-
pholipid (phosphatidylcholine/phosphatidylinositol 3:1 w/w), 0.1 mol/L potas-
sium phosphate, and 20% BSA, and activity was determined as the release of
3H-FFA (28).
Glucose uptake. Myotubes or isolated extensor digitorum longus muscles
were pretreated with 100 nmol/L PEDF or an equal volume of PBS for 2 h.
2-Deoxy-D-glucose uptake was measured as described (3).
Insulin tolerance test. Mice were injected with PEDF (50 µg i.p.) or 0.9%
saline and 2 h later with insulin (0.5 units/kg; Actrapid, Novo Nordisk, Bagsværd,
Denmark). Tail blood was collected at 15-min intervals for 90 min, and blood
glucose was determined using a glucometer (Accu-Chek, Roche Diagnostics,
Mannheim, Germany).
Cell fractionation, immunoﬂuorescence analysis, and immunoblot
analysis. Methods described in Supplementary Methods.
Quantitative RT-PCR. RNA was extracted in Qiazol reagent, followed by
isolation using an RNeasy Tissue Kit (Qiagen, Doncaster, Victoria, Australia).
RNA quantity was determined at 260 nm (NanoDrop p2000 Spectrometer,
Biolab, Clayton, Australia), reverse transcribed (Invitrogen, Mt. Waverley,
Victoria, Australia), and gene products were determined by real-time quanti-
tative RT-PCR (ep realplex Mastercycler, Eppendorf, Hamburg, Germany)
using TaqMan Assays-on-Demand (Applied Biosystems, Scoresby, Victoria,
Australia). 18S was used as a reference gene and did not vary between groups.
The mRNA levels were determined by a comparative CT method.
Electrospray ionization–tandem mass spectrometry of muscle lipids.
ATGL
2/2 and Wt littermates were injected with recombinant PEDF or saline
at 0700 h and allowed access to food and water. Mice were killed at 1600 h,
and the vastus lateralis muscle was removed. A 60-mg portion was homoge-
nized in PBS, and 50 mg protein (10–20 mL) was extracted with chloroform/
methanol (2:1; 20 volumes) after the addition of internal standards. Analysis
was performed by electrospray ionization–tandem mass spectrometry using
a PE Sciex API 4000 Q/TRAP mass spectrometer with a turbo-ionspray source
and Analyst 1.5 data system. Quantiﬁcation of individual lipid species was
performed using scheduled multiple-reaction monitoring in positive ion mode.
For detailed methods see Supplementary Methods.
Statistical analysis. Statistical analysis was performed using unpaired Stu-
dent t test. A two-way ANOVA with repeated measures was applied where
appropriate, and a Student-Newman-Keuls post hoc analysis was performed.
Statistical signiﬁcance was set a priori at P , 0.05.
RESULTS
PEDF enhances basal adipose tissue lipolysis in an
ATGL-dependent manner. We previously demonstrated
that PEDF increases basal lipolysis in 3T3-L1 adipocytes,
however, the mechanism remained unresolved (3). ATGL
is a critical mediator of triacylglycerol lipolysis in multiple
tissues (19,21,23) and appears to interact with PEDF (24).
ATGL was recently proposed to be a receptor for PEDF
(17). This is a curious observation because ATGL has pre-
viously been localized to lipid droplets or the cytoplasm of
adipocytes (19,23,29,30). We also veriﬁed the localization of
ATGL to lipid droplets in adipocytes (Fig. 1A); however, we
failed to observe any detectable ATGL in puriﬁed plasma
membrane fractions isolated from adipocytes (Fig. 1B), and
very little was detected in myotubes (Fig. 1B).
We next sought to determine whether ATGL is required
for PEDF’s stimulatory effects on lipolysis. PEDF in-
creased basal lipolysis by ;25% in isolated adipose tissue
explants (Fig. 1C, Supplementary Fig. 1A) but did not af-
fect b-adrenergic stimulated lipolysis (Fig. 1D, Supple-
mentary Fig. 1B). This stimulatory effect of PEDF on basal
lipolysis was not evident in explants from ATGL
2/2 mice
(Fig. 1C) and may be explained by a direct interaction
between ATGL and PEDF as previously shown (17,24). It
is unlikely that the other key lipolytic enzyme, HSL, is
important for this process because adipose tissue from
HSL
2/2 mice exhibited PEDF-stimulated lipolysis (Fig. 1C).
The PEDF-induced glycerol release in HSL
2/2 explants
suggests activation of another diacylglycerol lipase(s), as
observed in HSL
2/2 mice with b-adrenergic stimulation
(31,32), and/or reﬂects an increased availability of di-
acylglycerol substrate for HSL in Wt mice. Interestingly,
plasma PEDF is elevated during fasting and reduced with
refeeding in mice (Fig. 1E), which is temporally consistent
with lipolysis rates and therefore a prolipolytic role for
PEDF.
Next, we assessed the in vivo relevance of these
observations. An acute PEDF injection into Wt mice in-
creased plasma glycerol; however, these effects were
abolished in ATGL
2/2 mice (Fig. 1F). Collectively, these in
vitro and whole-animal studies demonstrate that ATGL is
required for PEDF’s lipolytic effects.
PEDF alters whole-body energy metabolism by mod-
ulating fatty acid oxidation. Having established that
PEDF increases basal lipolysis and thereby fatty acid avail-
ability, we next assessed PEDF’s effects on whole-body
energy homeostasis. PEDF administration did not affect
total energy expenditure (Fig. 2A), daily physical activity
(Fig. 2B), or food intake (data not shown) in Wt mice.
Whole-body substrate oxidation was calculated by indirect
calorimetry, and PEDF administration was shown to delay
the diurnal switch from carbohydrate to fat oxidation in the
fasted state (Fig. 2C). We repeated these experiments in
ATGL
2/2 mice and observed a mild decrease in 24-h oxygen
consumption (Fig. 2D) and no change in daily physical
activity (Fig. 2E). Whole-body carbohydrate oxidation was
elevated in ATGL
2/2 mice, as reported previously (18,33);
however, the PEDF-induced alterations in substrate me-
tabolism were not evident (Fig. 2F).
Intracerebroventricular PEDF does not affect energy
expenditure or substrate partitioning. Hypothalamic
sensing of nutrients and hormones regulates whole-body
energy homeostasis, affecting both feeding and energy ex-
penditure (34). Accordingly, we examined whether PEDF
was exerting metabolic effects by centrally mediated path-
ways. We ﬁrst established the presence of PEDF and ATGL
transcripts in the hypothalamus (Fig. 3A). To determine
the central effects of PEDF on energy metabolism, intra-
cerebroventricular PEDF or aCSF was administered in lean
mice. Whole-body energy expenditure (Fig. 3B), substrate
partitioning (Fig. 3C), food intake, and activity (not shown)
were not altered with the ICV PEDF injection. ICV PEDF
did not inﬂuence the expression of hypothalamic neuro-
peptides that modulate feeding and energy metabolism
(Fig. 3D).
PEDF inﬂuences fatty acid metabolism via direct
effects on peripheral tissues
Cell culture studies. Because skeletal muscle is a major
site for whole-body substrate metabolism, these whole-body
metabolic effects raise the possibility that PEDF exerts
negative effects on skeletal muscle by interfering with fatty
M.L. BORG AND ASSOCIATES
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in cultured myotubes. PEDF did not affect fatty acid up-
take into myotubes (Fig. 4A) or the incorporation of ex-
tracellular fatty acids into triacylglycerol (P = 0.07, Fig. 4B)
and diacylglycerol (Fig. 4C), indicating that PEDF does not
acutely affect fat storage in muscle. PEDF increased in-
tracellular muscle TG hydrolase activity and the oxidation
of fatty acids derived from intramyocellular triacylglycerol
(Supplementary Fig. 2A and B). Concomitantly, PEDF re-
duced exogenous fatty acid oxidation by 23% (representing
those fatty acids derived from outside the cell, Fig. 4D).
Notably, the rate of exogenous fatty acid oxidation was
90% higher than TG-derived fatty acid oxidation; hence,
total fatty acid oxidation was reduced by 18% in PEDF-
treated myotubes. The net reduction in overall fatty acid
oxidation was due to reduced “complete oxidation” (
14CO2
production: ↓40 6 7% in PEDF, n =1 2 –15, P , 0.05),
suggestive of defective mitochondrial fatty acid oxidation
and not impaired mitochondrial fatty acid transport.
Intramyocellular triacylglycerol levels were increased in
myotubes (Fig. 4E), demonstrating that the incorporation of
new fatty acids into the triacylglycerol pool exceeded the
capacity for PEDF-mediated intramyocellular triacylglycerol
hydrolysis and whole-cell fatty acid oxidation. In support
of this conclusion, when myotubes were incubated in the
absence of free fatty acids, PEDF treatment resulted in
intramyocellular triacylglycerol depletion (Supplementary
Fig. 2C).
Animal studies. PEDF also blunted fatty acid oxidation
in isolated soleus muscle of Wt mice (Fig. 4F). Studies
in mice also revealed effects of nutritional status. When
PEDF was injected into fasting mice, plasma FFA levels
were increased and muscle TG was unchanged (Supple-
mentary Fig. 3A and B), whereas PEDF administration in
mice fed ad libitum did not affect plasma FFA, and skeletal
muscle TG was decreased (Supplementary Fig. 3D and E).
Studies in isolated soleus muscle from ATGL
2/2 revealed
no effects of PEDF on fatty acid oxidation (Fig. 4F), TG
hydrolase activity, or esteriﬁcation into triacylglycerol and
diacylglycerol (Supplementary Fig. 4A–C). These data in-
dicated that PEDF interacts with ATGL to generate a signal
that disrupts mitochondrial function. To test this notion, we
examined whether PEDF alters respiration in mitochondria
isolated from Wt mice. Surprisingly, PEDF had no effect on
mitochondrial respiration in the absence or presence of
ADP, oligomycin, or carbonyl cyanide p-[triﬂuoromethoxy]
FIG. 1. ATGL is the major target of PEDF-mediated lipolysis in adipose tissue. A: Immunoﬂuorescence microscopy shows distribution of ATGL in
the cytoplasm and around lipid droplets in 3T3-L1 adipocytes. Notably, ATGL is not observed at the plasma membrane (PM) or with endosomal
(early endosome antigen 1 [EEA1]: green) or Golgi markers (gm130: blue). B: ATGL colocalizes with the cytoplasmic marker tubulin, but not with
membrane markers in a subcellular fractionation. Western blot shows location of various subcellular markers in a fractionation from 3T3-L1
adipocytes (top) and L6 myotubes (below). +PM, plasma membrane–containing fraction. C: Epididymal fat pads were excised from lean ATGL
2/2,
HSL
2/2, or Wt littermates, and lipolysis was assessed as glycerol release into the buffer. PEDF: 100 nmol/L (n = 4 per group). *P < 0.05 vs. vehicle
within the same genotype. D: PEDF (100 nmol/L) does not affect b-adrenergic–stimulated lipolysis in epididymal fat pads. Fat pads were incubated
for 2 h in isoproterenol (1 mmol/L), and glycerol release was determined (n = 4 per group). E: Immunoblot of plasma PEDF in mice fasted for 16 h
or 2 h after refeeding. F: In vivo lipolysis is increased by PEDF. Lean ATGL
2/2 or Wt mice were injected with PEDF intraperitoneally, blood was
obtained after 30 min, and glycerol was assessed in the plasma (n = 6 mice per group). *P < 0.05 vs. vehicle. Data in graphs are mean 6 SEM.
(A high-quality digital representation of this ﬁgure is available in the online issue.)
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PEDF appears to bind endothelial cell-surface F1Fo-ATP
synthase and reduce its ATP synthesis activity (35), the
addition of PEDF to isolated mitochondria in vitro did not
affect respiration (data not shown).
Prolonged PEDF administration affects lipid metabolism
in skeletal muscle. We next examined the effects of pro-
longed PEDF administration on skeletal muscle fatty acid
metabolism. C57Bl/6 mice were continuously infused with
recombinant PEDF or saline for 5 days (3) and muscles
were excised. Fatty acid uptake and fatty acid storage into
triacylglycerol were not affected by PEDF treatment (data
not shown), whereas fatty acid oxidation was reduced by
22% (saline: 3.7 6 0.2 vs. PEDF: 2.9 6 0.3 nmol/mg/min, P =
0.05). Further studies revealed that PEDF downregulates
the expression of genes involved in fatty acid b-oxidation
and oxidative phosphorylation (Fig. 4G). Genes involved in
fatty acid uptake and triacylglycerol metabolism were un-
affected. Collectively, PEDF modulates whole-body energy
homeostasis by impairing skeletal muscle fatty acid metab-
olism by both acute biochemical mechanisms and longer-
term transcriptional suppression of b-oxidation and oxidative
phosphorylation genes.
PEDF has mild effects on liver triacylglycerol metab-
olism. Dysfunctional liver lipid metabolism leads to steatosis
and insulin resistance. Forced ATGL expression in obese
mice (36,37) reduces liver triacylglycerol, and livers of
PEDF
2/2 mice store more triacylglycerol (24). Here, we
showed that acute PEDF administration in vivo increased
triacylglycerol hydrolase activity in liver lysates from Wt but
not ATGL
2/2 mice (Supplementary Fig. 6); however, this
did not alter TG content in fasted or ad libitum–fed mice
(Supplementary Fig. 3C and F). The absence of a functional
effect may reﬂect the low hepatic ATGL abundance (27).
ATGL is required for PEDF’s inhibitory effect on
skeletal muscle glucose metabolism. To test whether
ATGL is required for PEDF’s inhibitory effects on insulin-
mediated glucose disposal (3,14), myocytes were gener-
ated from skeletal muscle satellite cells of ATGL
2/2 and Wt
littermate mice and differentiated into multinucleated myo-
tubes. As expected, insulin increased glucose uptake in both
Wt and ATGL
2/2 myotubes (Fig. 5A). PEDF reduced insulin-
mediated glucose uptake in Wt myotubes, but this effect was
completely abrogated in ATGL
2/2 myotubes, thereby dem-
onstrating a role for ATGL in PEDF’s inhibition of insulin-
mediated glucose metabolism (Fig. 5A). These effects were
FIG. 2. PEDF alters whole-body fatty acid metabolism. A–C: Lean C57Bl/6 mice were injected with recombinant PEDF or sterile saline and placed in
a metabolic monitoring station. Oxygen uptake (VO2; A) and total activity (B) were similar between groups. C: The respiratory exchange ratio
(RER) was assessed during the light and dark cycles and was increased during the early phase of the light cycle in PEDF-treated mice (n = 6 mice
per group). *P < 0.05 vs. vehicle at the corresponding time. D–F:V O 2, activity, and the RER were assessed in ATGL
2/2 mice after recombinant
PEDF or sterile saline administration (n = 4 per group). #P < 0.05, main effect for treatment. All data are presented as means 6 SEM.
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2/2
mice ex vivo (Fig. 5B). We next performed an insulin toler-
ance test in vivo and observed a pronounced reduction in
systemic insulin sensitivity in Wt mice with PEDF treatment
(Fig. 5C) ,b u tn oe f f e c to fP E D Ft ob l u n ti n s u l i ns e n s i t i v i t yi n
ATGL
2/2 mice (Fig. 5D).
Altogether, these results demonstrate that PEDF in-
duces insulin resistance in skeletal muscle via an ATGL-
dependent process. Because ATGL catalyzes multiple
functions in lipid metabolism (21), we performed an un-
biased lipidomics analysis of skeletal muscle to determine
whether PEDF action produces a lipid that may interfere
with insulin signal transduction. PEDF reduced total tri-
acylglycerol in Wt mice, but no effects were noted in
ATGL
2/2 mice. Aside from sphingomyelin, which was in-
creased by 17%, there were no changes in the total contents
of other lipids (Table 1). There were some minor changes in
several lipid species (Supplementary Table 1).
DISCUSSION
Obesity is associated with defective fatty acid metabolism
in adipose tissue, liver, and muscle. We previously identi-
ﬁed PEDF as an adipocyte-secreted factor that is elevated
in obesity and causes insulin resistance (3). Here, we used
genetic approaches in cell culture models and in vivo func-
tional experiments to reveal several important metabolic
functions of PEDF: 1) PEDF increases adipose tissue li-
polysis in an ATGL-dependent manner; 2)P E D Fa l t e r ss y s -
temic fat metabolism by reducing skeletal muscle fatty acid
oxidation and suppressing gene expression of b-oxidation/
oxidative metabolism proteins; and 3) ATGL is implicit in
PEDF-mediated insulin resistance.
A unique feature of PEDF is the absence of an active
c-reactive loop that renders the protein noninhibitory. Thus,
an important question posed by these experiments is how
does PEDF exert its metabolic actions? PEDF is a growth
factor that presumably binds to cell surface receptor(s)
and triggers intracellular signaling (17,38). Although one
group identiﬁed ATGL as a lipase-linked membrane-bound
receptor for PEDF (17), we and others have been unable
to detect ATGL at the plasma membrane in adipocytes
(19,22,30). PEDF likely exerts some biologic effects via
a receptor at the plasma membrane (38). We cannot ex-
clude the possibility that PEDF acts by modifying the ac-
tivity of another bioactive molecule, but it is notable that
serpin activity for this protein remains undetected.
PEDF leads to the rapid activation of the Jun NH2-terminal
kinase and extracellular signal–related kinase signaling
pathways, consistent with a PEDF receptor–mediated
event (3). It should be noted that the latter was retained
in muscle of ATGL
2/2 mice, again making it unlikely that
ATGL is the PEDF receptor. It is also possible that PEDF
is transported across the plasma membrane to exert its
biologic actions. Chung et al. (24) incubated HepG2 cells
with recombinant His-tagged PEDF and demonstrated
uptake of PEDF into cells and trafﬁcking to intracellular
lipid droplets. Others have shown high-afﬁnity binding of
recombinant PEDF to ATGL (17). Thus, PEDF appears to
be exerting its biologic effects by independent mecha-
nisms: 1) activating plasma membrane receptors and
downstream signaling and 2) via the interaction of PEDF
with ATGL, perhaps after sarcolemmal transport of
PEDF. This study was designed to examine the metabolic
effects of PEDF and the requirement of ATGL for these
processes.
FIG. 3. PEDF’s metabolic effects do not depend on central actions. A: The hypothalamus of C57Bl/6 mice was excised, and 18S, PEDF, and ATGL
mRNA expression were assessed by qRT-PCR (n =8 ) .B: C57Bl/6 mice were injected with 0.9 mg PEDF or aCSF and placed in a metabolic mon-
itoring station for assessment of oxygen uptake (VO2). C: RER was also assessed (n = 8 for PEDF and n = 11 for vehicle). D: Mice were injected
with 0.9 mg PEDF or aCSF, and the hypothalami were excised after 6 h to assess mRNA of hypothalamic neuropeptides that modulate feeding
and energy metabolism. Pro-opiomelanocortin (POMC), agouti-related peptide (AgRP), neuropeptide Y (NPY), and cocaine- and amphetamine-
regulated transcript (CART) were measured (n = 8 per group). All data are presented as means 6 SEM.
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triacylglycerol stored in intracellular lipid droplets (19,21–
23,39) and possesses transacylase activity (21). By using
genetic ATGL and HSL ablation, we extended our previous
observation that PEDF induces adipocyte lipolysis (3) by
demonstrating that PEDF-mediated lipolysis is dependent
on ATGL. The ﬁnding of a greater PEDF-induced FFA re-
lease in Wt mice (42%) compared with glycerol release (20%)
is also consistent with PEDF stimulating ATGL, which does
not possess diacylglycerol lipase activity (19).
A previous study showed that triacylglycerol content
in PEDF
2/2 hepatocytes was elevated and the addition
of recombinant PEDF reduced triacylglycerol content
(24). These authors used a nonspeciﬁc suicide inhibitor,
(bromomethylene)-3-(1-naphthalenyl)-2H-tetrahydropyran-
2-one, that blocks all calcium-independent phospholipase A2
lipase activity, including ATGL, and reported an attenuation
of PEDF’s apparent lipolytic effects. We showed that PEDF
can increase TG hydrolase activity in the liver, but this is not
sufﬁcient to alter triacylglycerol content. This is likely to
reﬂect the relatively low abundance of ATGL in the liver
compared with the adipocyte (19). Our studies in mice also
revealed an increase in plasma PEDF levels during fasting,
which is temporally associated with increases in adipocyte
lipolysis. Thus, PEDF is a lipolytic hormone that mobilizes
fatty acids from triacylglycerol stores. As PEDF is elevated
in obesity and type 2 diabetes (9,12), it may contribute to the
increased systemic mobilization of fatty acids frequently
observed in these conditions (40,41).
An imbalance between fatty acid delivery, storage, and
oxidation contributes to skeletal muscle lipid accumula-
tion, which is mechanistically linked to the development of
FIG. 4. PEDF modulates fatty acid (FA) metabolism in skeletal muscle. L6 myotubes were treated with 100 nmol/L PEDF or saline (vehicle) for 2 h.
Total FA uptake (A), incorporation of FA into triacylglycerol (TAG; B) or diacylglycerol (DAG; C), and FA oxidation (D) were assessed using
0.5 mmol/L [1-
14C] palmitate (n =6 –12 for each group). E: Myotube TAG content is shown after 6-h treatment with 0.5 mmol/L oleate in the in-
cubation media (n =4 –6 per group). All data are presented as means 6 SEM. *P < 0.05 vs. vehicle. F: PEDF (100 nmol/L) reduces FA oxidation in
intact skeletal muscle. Soleus muscles were removed from ATGL
2/2 and Wt littermates before assessment of FA oxidation using 0.5 mmol/L [1-
14C]
oleate ex vivo. *P < 0.05 vs. vehicle within the same genotype (n = 6 per group). G: Genes associated with FA oxidation and mitochondrial bio-
genesis (left) and TAG storage and degradation (right) were assessed in vastus lateralis of mice treated with saline or PEDF for 5 days (n = 6 for
each group). *P < 0.05 vs. vehicle.
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some of PEDF’s in vivo metabolic effects depend on nu-
tritional status. Total energy expenditure was not altered
by PEDF, but substrate utilization was affected: PEDF
reduced daily fatty acid oxidation by ;5% (P = 0.02), an
effect that was mediated by suppressing the normal di-
urnal substrate switching from carbohydrate oxidation in
the fed state (dark) to fatty acid oxidation in the fasted
FIG. 5. PEDF causes skeletal muscle insulin resistance in an ATGL-dependent manner. A: 2-Deoxy-D-glucose (2-DG) uptake experiments in primary
myotubes. Wt (□) and ATGL
2/2 (■) myotubes were pretreated with saline or PEDF (100 nmol/L) for 2 h. The media was removed, and basal and
insulin-stimulated 2-DG uptake was determined (n = 6 for each group where each experiment was performed in triplicate on two occasions). *P <
0.05 vs. vehicle within the same genotype. Values are means 6 SEM. B: Extensor digitorum longus muscles were removed from ATGL
2/2 (■) and
Wt littermates (□) before assessment of insulin-stimulated glucose uptake (n =4 –6 for each group where each experiment was performed on two
occasions). *P < 0.05 vs. –PEDF within the same genotype. Values are means 6 SEM. Insulin tolerance tests were performed in Wt (C) and ATGL
2/2
mice (D). PEDF was injected intraperitoneally 2 h before insulin administration. PEDF (n =6 –7 per treatment). *P < 0.05 vs. corresponding time
point within the same genotype.
TABLE 1





Vehicle PEDF Vehicle PEDF
Triacylglycerol 202,356 6 50,054 72,565 6 8,131* 243,282 6 17,744 210,888 6 52,728
Diacylglycerol 53,860 6 4,521 42,232 6 2,304 75,273 6 26,727 54,336 6 24,595
Phosphatidylglycerol 1,597 6 181 2,052 6 77 1,789 6 75 1,873 6 101
Phosphatidylinositol 20,493 6 4,134 22,446 6 2,594 21,346 6 2,273 20,742 6 1,775
Phosphatidylethanolamine 34,203 6 3,803 40,704 6 1,193 37,618 6 952 38,991 6 1,299
Phosphatidylserine 8,156 6 463 7,630 6 413 8,749 6 992 7,744 6 385
Cholesterol ester 3,738 6 1,348 4,606 6 1,008 4,670 6 1,113 3,928 6 620
Sphingomyelin 261,548 6 3,995 305,516 6 15,202† 355,098 6 22,736 320,042 6 14,868
Ceramide 1,924 6 123 1,850 6 111 1,874 6 147 1,809 6 60
Dihydroceramide 253 6 18 372 6 75 302 6 35 266 6 44
Dihexosylceramide 205 6 45 209 6 42 250 6 24 208 6 24
Monohexosylceramide 797 6 118 635 6 96 893 6 216 624 6 57
GM3 ganglioside 152 6 7 120 6 12 135 6 13 156 6 13
Lysophosphatidylcholine 5,212 6 1,897 3,110 6 303 2,907 6 320 3,135 6 277
Units are expressed as pmol/mmol phosphatidylcholine. Wt, Wt + PEDF, ATGL
2/2 n = 4; ATGL
2/2 + PEDF n = 8. Values are mean 6 SD. *P ,
0.05 vs. ATGL
2/2 PEDF. †P , 0.05 vs. vehicle of the same genotype.
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inﬂexibility,” refers to an impaired capacity to adjust sub-
strate selection in response to a changing nutrient supply
and is a common feature of obesity and its related dis-
eases, including type 2 diabetes (43).
Skeletal muscle is a major regulator of whole-body fatty
acid disposal and oxidative enzyme activity, and tissue
fatty acid oxidation is reduced in obesity and type 2 di-
abetes (44–48). Studies in cultured myotubes and isolated
muscles conﬁrmed the whole-body metabolic analysis and
revealed that PEDF reduces fatty acid oxidation. PEDF
appears to be inducing concurrent functions in muscle that
leads to a “lipotoxic” environment (3). PEDF increased
muscle triacylglycerol lipase activity and the oxidation
of the liberated triacylglycerol-derived fatty acids. The in-
creased intramyocellular ﬂux competed with fatty acids
derived from extracellular sources, which accounted for
;25% of the reduction in fatty acid oxidation from ex-
tracellular sources, suggesting that a mechanism other
than substrate ﬂux reduces total fatty acid oxidation. The
net effect of this acute dysregulation in vitro is muscle
lipid storage, demonstrating that the ﬂux and oxidation of
fatty acids derived from intracellular triacylglycerol is
less than the uptake and oxidation of exogenous fatty
acid. Our studies examining the effect of nutritional sta-
tus (fast vs. fed) on PEDF actions in mice support this
conclusion.
We have also shown that fatty acid oxidation is reduced
with 5-day PEDF treatment, and subsequent transcript pro-
ﬁling in skeletal muscle revealed that PEDF decreased the
expression of genes associated with fatty acid b-oxidation
and mitochondrial biogenesis. This result was somewhat
unexpected, because stimulation of ATGL would be ex-
pected to produce fatty acid ligands that activate peroxi-
some proliferator–activated receptors and increase the
expression of genes involved in mitochondrial fat oxida-
tion (49). PEDF likely targets several transcription factors
or coactivators, given its known pleiotropic actions (13).
Collectively, PEDF modulates whole-body energy homeo-
stasis by impairing skeletal muscle fatty acid metabolism
acutely via the suppression of fatty acid oxidation and, in
the longer-term, by inducing transcriptional suppression
of several genes involved with b-oxidation and oxidative
phosphorylation.
The accumulation of ectopic lipid contributes to insulin
resistance, and interventions that stimulate fatty acid oxi-
dation can decrease lipid accumulation in muscle that as-
sociates with insulin sensitization (50–52). We previously
showed that PEDF caused insulin resistance in lean, healthy
mice in association with lipid metabolite accumulation (3).
Here, we extended those studies by demonstrating that
ATGL is required for PEDF-induced insulin resistance in
muscle. Studies in primary muscle cells and isolated intact
muscles demonstrate that this effect is intrinsic to muscle
and is not affected by other known negative regulators of
insulin action such as altered circulating lipids, hormones,
or proinﬂammatory cytokines. These studies supported
the premise that PEDF-mediated activation of ATGL pro-
duces lipid ligands that inhibit insulin action in muscle.
However, our detailed lipidomics analysis did not reveal
this lipid signal, if one exists. Notably, we did not measure
FFA species, and others have shown that speciﬁc fatty
acids (e.g., C16:1n7-palmitoleate) can modulate systemic
metabolism (53).
Finally, impaired mitochondrial function has been
linked with insulin resistance development (46,48), and
PEDF inhibits endothelial cell surface ATP synthesis ac-
tivity (35). Our studies do not support a role for PEDF in
acute mitochondrial dysfunction; however, we cannot ex-
clude the possibility that PEDF is producing a metabolite
that can inﬂuence mitochondrial function in vivo. Further
studies are required to address this possibility.
In summary, these studies have extended the under-
standing of PEDF’s biologic targets and metabolic actions.
These results show that aspects of defective lipid metabo-
lism in obesity can be recapitulated with PEDF. Speciﬁcally,
PEDF enhances basal adipose tissue lipolysis via ATGL,
reduces skeletal muscle fatty acid oxidation, and requires
ATGL to induce insulin resistance. The interaction between
PEDF and ATGL contributes to the metabolic dysregulation
that results in lipid deposition and insulin resistance in
obesity and type 2 diabetes, conditions characterized by
increased PEDF levels (3,9,11,12).
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